Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Lutetium-177 zadavotide guraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Lantheus Medical Imaging
Most Recent Events
- 13 Jan 2025 Status changed from recruiting to suspended.
- 18 Sep 2023 New trial record